- Manufacturing considerations and adaptations to accelerate scale-up, increase workflow efficiency, and standardize GMP manufacturing processes for RNA vaccines and therapeutics
- How to improve operational flexibility to address novel molecules and expand targeted delivery to new applications beyond mRNA vaccine development
- Strategies to increase manufacturing capacity for different stages of clinical development and commercial manufacturing of RNA-LNP drug products
—
Martin Rabel
Sr. Field Application Scientist
Precision NanoSystems Inc.
Martin Rabel, Dipl.-Pharm., Ph.D. currently works as a Senior Field Application Scientist for Precision NanoSystems ULC supporting clients in Central Europe, Middle East, and Africa (EMEA). He obtained his pharmaceutical license as well as a postgraduate diploma from the Friedrich-Schiller-University Jena working on Bacterial Nanocellulose (BNC) nanoparticles for gene delivery applications. His Ph.D. research focused on the development of animal-free simulation models for the development of complex diagnostic nanoparticles (IONP) and other nanomedicines as well as nanoparticle characterization and manufacturing methods. He joined Precision NanoSystems ULC in 2019 as Field Application Scientist. He is specialized in the development of novel nanomedicines using PNI´s microfluidic NanoAssemblr platform and gene delivery reagents. His expertise spans formulation development, optimization as well as scale-up including GMP manufacturing.
—
Precision NanoSystems, now part of Cytiva, is a global leader in ushering in the next wave of genomic medicines in infectious diseases, cancer, and rare diseases. We work with the world’s leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genomic medicines.
